Ignite Creation Date:
2024-05-05 @ 5:02 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00370916
Status:
COMPLETED
Last Update Posted:
2015-04-07
First Post:
2006-08-30
Brief Title:
Reducing Transition Drug Risk
Sponsor:
US Department of Veterans Affairs
Organization:
VA Office of Research and Development
Study Overview
Official Title:
Reducing Transition Drug Risks After Patient Transfer
Status:
COMPLETED
Status Verified Date:
2010-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patient transfer between sites of care is regular practice during an episode of care in our current health care system Yet inter-site transfer is associated with lapses in care quality that adversely affect patient outcomes A common iatrogenic harm precipitated at the time of transfer is harm from drug prescribing or adverse drug events ADEs In this study we will evaluate a medication reconciliation tool developed to help providers make effective prescribing decisions at the time of transfer between VA sites of care Improved Prescribing after Transfer IPT We will evaluate the quantitative effectiveness of the tool in reducing transition drug risk and ADEs We additionally will conduct focus group discussions and cognitive task analysis among end-users to better understand how providers make drug-prescribing decisions at the time of transfer and to assess factors influencing effective use of the tool
Detailed Description:
This is a 2-phase study in which we will employ mixed quantitative and qualitative methods to conduct an evaluation of the IPT tool while improving our understanding of provider prescribing decisions at the time of patient transfer In Phase 1 we will conduct a 5-month controlled trial among all admissions to 2 units at JJ Peters Bronx VA Medical Center We will compare IPT with usual care and compare physician and pharmacist forms of IPT implementation with regard to as primary outcome transition drug risk and as secondary outcomes ADEs provider prescribing-decisions and hospital utilization In Phase 2 which will run concurrently with Phase 1 we will perform cognitive task analysis to examine providers decision-making and to map IPT tool functions while providers interface with the tool and perform focus group interviews with representative IPT users to identify factors that facilitate or hinder adoption Results of cognitive analysis and focus groups will be used to identify tool deficiencies to consider for redesign
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None